ASTRA USA's ROPIVACAINE ANESTHETIC LESS TOXIC THAN BUPIVACAINE, ACCORDING TO ASTRA DATA; NAROPIN UNANIMOUSLY RECOMMENDED FOR APPROVAL BY FDA COMMITTEE
Executive Summary
Astra's plasma concentration studies for Naropin (ropivacaine) show the central nervous system toxicity threshold to be twice as high for ropivacaine as for bupivacaine (Astra's Sensorcaine and Sanofi Winthrop's Marcaine).